Premium Nahrungsergänzungsmittel | artgerecht

Fibrinogen Degradation: Causes, Significance & Diagnosis

Fibrinogen degradation is the biochemical process by which the clotting protein fibrinogen is broken down in the blood. It plays a central role in blood coagulation and wound healing.

Regular tips about health Regular tips about health

Things worth knowing about "Fibrinogen Degradation"

Fibrinogen degradation is the biochemical process by which the clotting protein fibrinogen is broken down in the blood. It plays a central role in blood coagulation and wound healing.

What is Fibrinogen Degradation?

Fibrinogen degradation (also called fibrinogenolysis) refers to the enzymatic breakdown of fibrinogen, a key glycoprotein found in blood plasma. Fibrinogen is produced in the liver and is a central component of the blood clotting cascade. When cleaved by the enzyme thrombin, fibrinogen is converted into fibrin, which forms a stable clot. The subsequent breakdown of this fibrin -- and of fibrinogen itself -- is carried out primarily by the enzyme plasmin through a process known as fibrinolysis.

Biological Significance

Fibrinogen serves several important functions in the body:

It is an essential coagulation factor (Factor I) required for the formation of blood clots that seal wounds.
It contributes to blood viscosity.
It acts as an acute-phase protein, with levels rising during inflammation.

Controlled degradation of fibrinogen and fibrin is critical to ensure that blood clots dissolve once wound healing is complete, preventing permanent vessel occlusion.

Mechanism of Fibrinogen Degradation

The degradation of fibrinogen proceeds through several steps:

Activation of plasminogen: Tissue plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA) convert inactive plasminogen into the active enzyme plasmin.
Cleavage by plasmin: Plasmin cleaves fibrinogen into fibrinogen degradation products (FDPs), including fragments X, Y, D, and E. Cleavage of cross-linked fibrin additionally produces D-dimers.
Elimination of breakdown products: The resulting degradation products are cleared from the bloodstream by the reticuloendothelial system (RES).

Clinical Relevance

Increased Fibrinogen Degradation

Accelerated or uncontrolled breakdown of fibrinogen can indicate or cause serious medical conditions:

Disseminated intravascular coagulation (DIC): A life-threatening disorder in which both coagulation and fibrinolysis are over-activated simultaneously, leading to rapid consumption of fibrinogen.
Primary hyperfibrinolysis: Excessive activation of the fibrinolytic system without prior coagulation.
Liver disease: Since fibrinogen is produced in the liver, impaired liver function can reduce fibrinogen levels and relatively accelerate its degradation.
Thromboembolic events: Following deep vein thrombosis or pulmonary embolism, fibrinolysis is activated, resulting in elevated D-dimer levels.

Reduced Fibrinogen Degradation

Insufficient degradation of fibrinogen and fibrin can lead to the persistence of blood clots, causing vessel occlusion and potentially triggering heart attack or stroke.

Diagnosis and Laboratory Parameters

Several laboratory tests are available to assess fibrinogen degradation:

Fibrinogen level: Normal blood levels range from 200 to 400 mg/dL. Reduced values indicate increased consumption or degradation.
D-dimer test: Elevated D-dimer levels indicate active fibrin degradation and suggest thrombosis or DIC.
Fibrin degradation products (FDPs): Measurement of breakdown products in blood to assess fibrinolytic activity.
Thromboelastography (TEG/ROTEM): Viscoelastic testing methods for overall assessment of clotting function, including fibrinolysis.

Therapeutic Approaches

Depending on the cause of pathological fibrinogen degradation, different treatment strategies are used:

Tranexamic acid: An antifibrinolytic agent that inhibits plasmin activation, thereby reducing excessive fibrinogen degradation. Frequently used in surgical procedures or severe bleeding.
Fibrinogen concentrate or fresh frozen plasma (FFP): Used to substitute fibrinogen when levels are critically low.
Treatment of the underlying condition: In DIC or liver disease, addressing the root cause is the primary focus of therapy.
Anticoagulants: When clotting risk is elevated and fibrinolysis is insufficient, blood-thinning medications may be used.

References

Levi M, van der Poll T. Disseminated intravascular coagulation: a review for the internist. Internal and Emergency Medicine. 2013;8(1):23-32.
Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Sub-Cellular Biochemistry. 2017;82:405-456.
World Health Organization (WHO). The Use of Fresh Frozen Plasma, Cryoprecipitate and Cryosupernatant. WHO Guidelines. 2004.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.